StockNews.com Upgrades Clorox (NYSE:CLX) to Buy

Clorox (NYSE:CLX) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday.

A number of other research analysts have also issued reports on CLX. Barclays boosted their price target on Clorox from $137.00 to $139.00 and gave the stock an “underweight” rating in a research report on Friday, November 1st. JPMorgan Chase & Co. upped their price objective on shares of Clorox from $148.00 to $174.00 and gave the stock a “neutral” rating in a report on Friday, October 11th. Evercore ISI lowered their target price on shares of Clorox from $140.00 to $139.00 and set an “underperform” rating on the stock in a research note on Monday, October 14th. BNP Paribas raised shares of Clorox to a “strong sell” rating in a research note on Friday, September 6th. Finally, TD Cowen upgraded shares of Clorox from a “sell” rating to a “hold” rating and increased their price objective for the company from $155.00 to $170.00 in a report on Wednesday, November 6th. Five equities research analysts have rated the stock with a sell rating, eight have given a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $155.38.

Clorox Stock Up 1.5 %

Clorox stock opened at $164.13 on Wednesday. The company has a debt-to-equity ratio of 11.08, a quick ratio of 0.62 and a current ratio of 1.00. Clorox has a one year low of $127.60 and a one year high of $171.37. The company has a 50-day simple moving average of $164.08 and a 200-day simple moving average of $152.48. The firm has a market capitalization of $20.32 billion, a P/E ratio of 57.19, a P/E/G ratio of 3.04 and a beta of 0.42.

Clorox (NYSE:CLX) last posted its earnings results on Wednesday, October 30th. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.36 by $0.50. The firm had revenue of $1.76 billion during the quarter, compared to analysts’ expectations of $1.64 billion. Clorox had a net margin of 4.78% and a return on equity of 316.08%. Clorox’s quarterly revenue was up 27.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.49 EPS. As a group, equities analysts expect that Clorox will post 6.85 earnings per share for the current year.

Institutional Investors Weigh In On Clorox

Several large investors have recently modified their holdings of the stock. Prospera Private Wealth LLC purchased a new stake in shares of Clorox during the third quarter valued at $27,000. Continuum Advisory LLC lifted its stake in Clorox by 300.0% during the third quarter. Continuum Advisory LLC now owns 184 shares of the company’s stock valued at $30,000 after buying an additional 138 shares in the last quarter. Innealta Capital LLC acquired a new position in shares of Clorox in the second quarter worth about $30,000. Trifecta Capital Advisors LLC increased its position in shares of Clorox by 139.8% in the second quarter. Trifecta Capital Advisors LLC now owns 223 shares of the company’s stock worth $30,000 after acquiring an additional 130 shares in the last quarter. Finally, Quarry LP raised its holdings in shares of Clorox by 99.1% during the second quarter. Quarry LP now owns 229 shares of the company’s stock valued at $31,000 after acquiring an additional 114 shares during the period. 78.53% of the stock is owned by institutional investors.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.